Pembrolizumab is indicated as monotherapy in adults both for patients with metastatic or locally advanced UC who have previously received a platinum therapy and for patients with metastatic or locally advanced UC whose tumor expresses PD-L1 with a combined positive score (CPS) ≥10%, who are not eligible for a cisplatin chemotherapy. Here, CD274 is linked to neoplasm.